SCHEMBL14699199

SCHEMBL14699199

NC(=O)c1[c]cn(Cc2noc3ccccc23)n1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.44
CA12 O43570 1/20 0.44
CA1 P00915 1/20 0.44
CA2 P00918 1/20 0.44
CA3 P07451 1/20 0.44
CA4 P22748 1/20 0.44
CA6 P23280 1/20 0.44
MAOB P27338 1/20 0.44
CA5A P35218 1/20 0.44
CA7 P43166 1/20 0.44
CA9 Q16790 1/20 0.44
CA13 Q8N1Q1 1/20 0.44
CA14 Q9ULX7 1/20 0.44
CA5B Q9Y2D0 1/20 0.44
KLKB1 P03952 1/20 0.39
SMN1; SMN2 Q16637 6/20 0.39
RAB9A P51151 5/20 0.39
NPC1 O15118 4/20 0.39
KDM4E B2RXH2 2/20 0.39
TP53 P04637 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1718132 0.74 PARP1 (0.48) KLKB1GAAALDH1A1HPGDPOLB
SCHEMBL16163410 0.71 NOTUM (0.47) SMN1; SMN2RAB9ANPC1MAPTALDH1A1
SCHEMBL15520038 0.70 LMNA (0.40) LMNASMN1; SMN2RAB9ANPC1KDM4E
SCHEMBL15520764 0.70 ALDH1A1 (0.48) LMNAMAOBCA5ARAB9ANPC1
SCHEMBL2793131 0.70 LMNA (0.58) LMNACA12CA1CA2CA3
SCHEMBL15520351 0.68 TSHR (0.43) LMNASMN1; SMN2RAB9ANPC1KDM4E
SCHEMBL4019841 0.68 CYP17A1 (0.39) LMNASMN1; SMN2KDM4ECYP3A4ALDH1A1
SCHEMBL13254720 0.68 LMNA (0.32) LMNASMN1; SMN2MAPT
SCHEMBL14699373 0.67 ADORA2A (0.47) LMNAKDM4ENPSR1
SCHEMBL15520768 0.67 LMNA (0.40) LMNAMAOBSMN1; SMN2RAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2742040-B1 INDAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE HOFFMANN LA ROCHE (CH) 2016-04-06 EP disclosed
US-20140309210-A1 INDAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2014-10-16 US disclosed
EP-2742040-A1 INDAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE F.HOFFMANN-LA ROCHE AG (CH) 2014-06-18 EP disclosed
WO-2013024011-A1 INDAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE F. HOFFMANN-LA ROCHE AG (CH) 2013-02-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140309210-A1 INDAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF CYP3A43, INSR, CYP2C19 LMNA 1835/4885CA12 2661/4885CA1 2119/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.